Blonanserin (Lonasen) is a relatively new atypical antipsychotic (approved by PMDA in January 2008) commercialized by Dainippon Sumitomo Pharma in Japan and Korea for the treatment of schizophrenia. Relative to many other antipsychotics blonanserin has an improved tolerability profile lacking side effects such as extrapyramidal symptoms excessive sedation or hypotension.
This page contains content from the copyrighted Wikipedia article "Blonanserin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
